Lexology June 5, 2025
The global trade landscape remains unpredictable with recent developments taking unexpected turns. Uncertainty created by evolving trade dynamics and regulatory scrutiny is bringing increasing pressure to bear on the life sciences sector. In the following article, we outline key updates that are particularly relevant to stakeholders in the life sciences industry.
1. Intensified antitrust enforcement in China’s pharmaceutical sector with individual liability on the rise
Recent enforcement actions:
- March 2025
- Three pharmaceutical companies were fined approximately RMB 223 million for collusion to fix prices and divide markets related to Neostigmine Methylsulfate Injection.
- One individual directly responsible for implementing the collusion was fined RMB 500,000.
- The first company to self-report and cooperate under the leniency programme received an 80%...
Today's Sponsors
Today's Sponsor